Givinostat is an oral histone deacetylase (HDAC) inhibitor approved by the FDA in 2024 to treat Duchenne patients ages 6 years and older. Pathologic upregulation of HDAC occurs in DMD, leading to ...

BridgeBio Pharma will seek US approval of its limb-girdle muscular dystrophy (LGMD) small molecule after the drug met its ...

BridgeBio said an experimental therapy for a rare form of muscular dystrophy succeeded in a key trial, potentially setting up ...

New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...

The major resemblance between teeth and bones is what they're made of: hard tissue composed of minerals, such as calcium, ...

Shares of BridgeBio Pharma rose after the company reported positive data in the phase three study of its treatment of limb-girdle muscular dystrophy. The stock rose 10% to $59.74 in premarket trading ...

Detailed price information for Edgewise Therapeutics Inc (EWTX-Q) from The Globe and Mail including charting and trades.

BridgeBio Pharma Inc.’s drug to treat a devastating muscle-wasting disorder met its goal in a late-stage trial, paving the ...

BridgeBio Pharma has caught Wall Street’s attention after the company shared positive Phase 3 results from its FORTIFY trial for BBP-418 in limb-girdle muscular dystrophy type 2I/R9. The treatment ...

Investing.com -- BridgeBio Pharma (NASDAQ:BBIO) stock rose 15% after reporting positive Phase 3 results for its small molecule BBP-418 in the treatment of limb-girdle muscular dystrophy type 2I/R9 ...

Peptides have become an increasingly important area of research in numerous scientific fields, especially for their diverse functions.

Columbus Yachts has released more details about the first unit in its Crossover line. The 138-foot "Big Naan" is a big, ...